Cumberland Pharmaceuticals Reports Q1 $3.3M Loss and $100M Apotex Brand Sale
CPIX•Cumberland Pharmaceuticals reported a Q1 net loss of $3.3 million on $9.1 million revenue and an adjusted loss of $0.13 per share. It agreed to sell its FDA-approved brands to Apotex for $100 million cash while retaining its ifetroban development pipeline, which holds Fast Track designation for Duchenne muscular dystrophy.
1. Q1 Financial Results
In Q1 2026, Cumberland’s portfolio delivered net revenues of $9.1 million, while operating expenses reached $12.3 million, resulting in a net loss of $3.3 million and an adjusted loss of $1.9 million, or $0.13 per share. The balance sheet at March 31 showed $71.0 million in assets, $49.7 million in liabilities, and $21.6 million in shareholders’ equity.
2. Strategic Transaction
Cumberland has agreed to sell its FDA-approved U.S. brands portfolio to Apotex for $100 million in cash, pending shareholder and regulatory approvals. The deal transfers branded commercial operations to Apotex and is intended to unlock value, enabling Cumberland to reallocate resources toward its development pipeline while maintaining majority ownership in Cumberland Emerging Technologies.
3. Pipeline Developments
Cumberland’s lead development candidate, ifetroban, has achieved breakthrough Phase II results in Duchenne muscular dystrophy-associated cardiomyopathy and holds Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA. Additional Phase II studies for systemic sclerosis and idiopathic pulmonary fibrosis are underway, with enrollment complete in the scleroderma trial and interim data pending in the IPF program.
